Core Insights - Dogwood Therapeutics, Inc. is advancing its first-in-class, non-opioid Nav 1.7 inhibitor, Halneuron, for treating chemotherapy-induced neuropathic pain (CINP) and is set to begin dosing the first patient in its Phase 2b clinical trial in Q1 2025 [1][3]. Company Overview - Dogwood Therapeutics is a development-stage biopharmaceutical company focused on creating new medicines for pain and fatigue-related disorders, with a proprietary non-opioid analgesic program centered on Halneuron [4]. - The company has a history of developing and commercializing successful pain therapeutics, including Celebrex, Lyrica, and Savella [3]. Product Development - Halneuron has shown statistically significant pain reduction in cancer-related pain in previous clinical trials, with an acceptable safety profile and no addiction potential [2]. - The market for chronic neuropathy treatment, particularly in cancer patients, is valued at approximately $1.5 billion, indicating a high unmet medical need [3]. Clinical Trials and Future Plans - Halneuron has been evaluated in over 700 patients across Phase 1 and Phase 2 studies, demonstrating its potential effectiveness [2]. - Interim data from the upcoming Phase 2 CINP study is expected in the second half of 2025 [4]. - The company is also advancing an antiviral program targeting illnesses related to dormant herpesviruses, with IMC-1 progressing to Phase 3 for fibromyalgia and IMC-2 moving into Phase 2b research for Long-COVID [4].
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025